Latest RUBY reports update at 2023-02-27: 2022 ∙ 2021 ∙ 2020

Rubius Therapeutics RUBY

$ 0.08 -33.55%

Rubius Therapeutics Financial Statements 2011-2024 | RUBY

Annual Financial Statements Rubius Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	11.7 M	851 M	612 M	606 M	534 M	209 M	101 M	-	-	-	-	-
Shares	90.3 M	88 M	80.6 M	78.7 M	39.3 M	45.7 M	8.54 M	-	-	-	-	-
Historical Prices	0.13	9.68	7.59	9.5	16.1	-	-	-	-	-	-	-
Net Income	-180 M	-197 M	-168 M	-163 M	-89.2 M	-43.8 M	-11 M	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-178 M	-195 M	-166 M	-170 M	-91.7 M	-43.3 M	-10.9 M	-	-	-	-	-
Interest Expense	3.86 M	6.43 M	4.18 M	2.59 M	464 K	309 K	149 K	-	-	-	-	-
EBITDA	-172 M	-187 M	-161 M	-167 M	-90.4 M	-42.3 M	-10.8 M	-	-	-	-	-
Operating Expenses	178 M	195 M	166 M	170 M	91.7 M	-	-	-	-	-	-	-
General and Administrative Expenses	30.8 M	53 M	50.3 M	57.2 M	39.9 M	22 M	2.45 M	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Rubius Therapeutics

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	-	90.4 M	90.3 M	90.1 M	90.1 M	89.8 M	89.5 M	82.3 M	81.1 M	80.8 M	80.5 M	80.3 M	80 M	79.1 M	78.4 M	77.5 M	79.2 M	62.3 M	8.73 M	8.36 M	15 M	8.08 M	7.87 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-62.9 M	-44.2 M	-52.4 M	-	-49 M	-50.2 M	-42.3 M	-40.5 M	-168 M	-168 M	-168 M	-44.5 M	-164 M	-164 M	164 M	-27.2 M	-26.4 M	-21.2 M	-89.2 M	-17.5 M	-11.9 M	-9.55 M	-5.23 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-61.6 M	-42.9 M	-50.9 M	-	-50 M	-49.9 M	-40.9 M	-39.7 M	-40.2 M	-37.7 M	-48.8 M	-45.4 M	-48.5 M	-41.3 M	-34.4 M	-29.1 M	-27.6 M	-20.4 M	-14.6 M	-17.5 M	-12 M	-9.03 M	-4.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	1.74 M	1.63 M	1.63 M	-	1.71 M	1.31 M	1.75 M	-	1.17 M	828 K	985 K	-	835 K	539 K	583 K	-	87 K	89 K	83 K	-	90 K	72 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-55.8 M	-39.7 M	-49.3 M	-	-45.7 M	-46.9 M	-39.4 M	-39.7 M	-35 M	-34.1 M	-47.1 M	-45.4 M	-46.2 M	-39.8 M	-33.7 M	-29.1 M	-26.7 M	-19.9 M	-14.4 M	-17.5 M	-11.7 M	-8.92 M	-4.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	61.6 M	42.9 M	50.9 M	-	50 M	49.9 M	40.9 M	39.7 M	40.2 M	37.7 M	48.8 M	45.4 M	48.5 M	41.3 M	34.4 M	29.1 M	27.6 M	20.4 M	14.6 M	17.5 M	12 M	9.03 M	4.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	-	7.3 M	9.91 M	12.6 M	-	12 M	13.9 M	13.2 M	-	12 M	11.6 M	12.7 M	-	15 M	13.8 M	13.5 M	-	13.2 M	9.02 M	5.1 M	-	5.85 M	4.21 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency